Publications

Detailed Information

A Personalized Cancer Vaccine that Induces Synergistic Innate and Adaptive Immune Responses

DC Field Value Language
dc.contributor.authorKuen, Da-Sol-
dc.contributor.authorHong, Jihye-
dc.contributor.authorLee, Suyoung-
dc.contributor.authorKoh, Choong-Hyun-
dc.contributor.authorKwak, Minkyeong-
dc.contributor.authorKim, Byung-Seok-
dc.contributor.authorJung, Mungyo-
dc.contributor.authorKim, Yoon-Joo-
dc.contributor.authorCho, Byung-Sik-
dc.contributor.authorKim, Byung-Soo-
dc.contributor.authorChung, Yeonseok-
dc.date.accessioned2024-06-13T02:10:42Z-
dc.date.available2024-06-13T02:10:42Z-
dc.date.created2023-08-08-
dc.date.created2023-08-08-
dc.date.issued2023-09-
dc.identifier.citationAdvanced Materials, Vol.35 No.36-
dc.identifier.issn0935-9648-
dc.identifier.urihttps://hdl.handle.net/10371/204221-
dc.description.abstractTo demonstrate potent efficacy, a cancer vaccine needs to activate both innate and adaptive immune cells. Personalized cancer vaccine strategies often require the identification of patient-specific neoantigens; however, the clonal and mutational heterogeneity of cancer cells presents inherent challenges. Here, extracellular nanovesicles derived from alpha-galactosylceramide-conjugated autologous acute myeloid leukemia (AML) cells (ECNV-& alpha;GC) are presented as a personalized therapeutic vaccine that activates both innate and adaptive immune responses, bypassing the need to identify patient-specific neoantigens. ECNV-& alpha;GC vaccination directly engages with and activates both invariant natural killer T (iNKT) cells and leukemia-specific CD8(+) T cells in mice with AML, thereby promoting long-term anti-leukemic immune memory. ECNV-& alpha;GC sufficiently serves as an antigen-presenting platform that can directly activate antigen-specific CD8(+) T cells even in the absence of dendritic cells, thereby demonstrating a multifaceted cellular mechanism of immune activation. Moreover, ECNV-& alpha;GC vaccination results in a significantly lower AML burden and higher percentage of leukemia-free survivors among cytarabine-treated hosts with AML. Human AML-derived ECNV-& alpha;GCs activate iNKT cells in both healthy individuals and patients with AML regardless of responsiveness to conventional therapies. Together, autologous AML-derived ECNV-& alpha;GCs may be a promising personalized therapeutic vaccine that efficiently establishes AML-specific long-term immunity without requiring the identification of neoantigens.-
dc.language영어-
dc.publisherWILEY-VCH Verlag GmbH & Co. KGaA, Weinheim-
dc.titleA Personalized Cancer Vaccine that Induces Synergistic Innate and Adaptive Immune Responses-
dc.typeArticle-
dc.identifier.doi10.1002/adma.202303080-
dc.citation.journaltitleAdvanced Materials-
dc.identifier.wosid001034243200001-
dc.identifier.scopusid2-s2.0-85165302296-
dc.citation.number36-
dc.citation.volume35-
dc.description.isOpenAccessN-
dc.contributor.affiliatedAuthorKim, Byung-Soo-
dc.contributor.affiliatedAuthorChung, Yeonseok-
dc.type.docTypeArticle-
dc.description.journalClass1-
dc.subject.keywordPlusACUTE MYELOID-LEUKEMIA-
dc.subject.keywordPlusT-CELLS-
dc.subject.keywordPlusDENDRITIC CELLS-
dc.subject.keywordPlusB-CELLS-
dc.subject.keywordPlusPHASE-I-
dc.subject.keywordPlusIMMUNOTHERAPY-
dc.subject.keywordPlusANTIGEN-
dc.subject.keywordPlusTHERAPY-
dc.subject.keywordPlusAML-
dc.subject.keywordPlusEXPRESSION-
dc.subject.keywordAuthoracute myeloid leukemia-
dc.subject.keywordAuthorcytotoxic T cells-
dc.subject.keywordAuthorextracellular nanovesicles-
dc.subject.keywordAuthoriNKT cells-
dc.subject.keywordAuthormemory immunity-
dc.subject.keywordAuthorpersonalized vaccines-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Related Researcher

  • College of Engineering
  • School of Chemical and Biological Engineering
Research Area biomaterials, nanomedicine, regenerative medicine

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share